Part,  Chapter, Paragraph

 1   II,     5.  2.  7|              Am Coll Cardiol 44: 720-32.~Hozawa A, Folsom AR, Sharrett
 2   II,     5.  3.  6|           men and women (Figures 5.3.32). Estimates of 1-year relative
 3   II,     5.  4.  3|           being the most performing (32%) and Cyprus being the least
 4   II,     5.  4.  3|           percentage varying between 32% (Finland) and 100% (Cyprus).~
 5   II,     5.  5.  3|             from 62 articles (out of 32 separate studies) were reviewed.
 6   II,     5.  5.  3| non-affective psychosis accounts for 32.2% world wide, of which
 7   II,     5.  5.  3|             affective-psychoses) was 32.2% (Kohn et al, 2004) worldwide;
 8   II,     5.  5.  3|             versus dogma. Schiz Bull 32: 195-197.~Middelboe T, Mackeprang
 9   II,     5.  5.  3|       behaviour therapy. Psychol Med 32(5):763-82.~Pitschel-Walz
10   II,     5.  5.  3|           Schizophrenia. psychoneuro 32:327-330.~Wölwer W, Buchkremer
11   II,     5.  5.  3|           generalized seizures in 26-32%, and unclassifiable seizures
12   II,     5.  5.  3|           policies~Prevalent cohorts~32~12.4~2.6~Preston and Clarke,
13   II,     5.  5.  3|            policies~Prevalent cohort~32~14.6~2.2~Svensson and Astrand,
14   II,     5.  5.  3|           found to range from 4.5 to 32 (Jallon, 2004). In a population-based
15   II,     5.  5.  3|            found prevalence rates of 32–58 and mean annual incidence
16   II,     5.  5.  3|              Rom J Neurol Psychiatry 32:115-122.~Bencsik K, Rajda
17   II,     5.  5.  3|           Neurosurg Psychiatry 74:29-32.~Sundström P, Svenningsson
18   II,     5.  6.  3|           Survey just under a third (32%) of all respondents said
19   II,     5.  6.  3|           reported as 0.6%, France 0.32% and Italy 0.13%. In women,
20   II,     5.  7.  3|            in all patients, and 21%, 32% and 72% for patients aged
21   II,     5.  7.  3|          recipients was much higher: 32% and 56%, respectively (
22   II,     5.  8.  4|             were assessed at 42% and 32%, respectively, in continuous
23   II,     5.  9. FB|             16% in Finland and up to 32% in UK. Secondly, among
24   II,     5.  9.  3|          from from 3.7% in Greece to 32.2% in UK. The existence
25   II,     5.  9.  4|           1989: relative risk (RR) 1.32 (1.12, 1.56), even in those
26   II,     5.  9.  4|        screening test for atopy) was 32.3%, with a higher prevalence
27   II,     5. 10.  7|           purposes. The EFSA Journal 32, 1-197.~htt ~ ~EU SCOOP (
28   II,     5. 10.  7|         infections. Clin Exp Allergy 32: 373-378.~Løvik M and Namork
29   II,     5. 11.  3|            sensitization prevalence (32.2 %) for nickel was observed
30   II,     5. 11.  7|              J Am Acad Dermatol 1995;32:212-217.~ ~Williams HC (
31   II,     5. 13    |          2004) were estimated to be €32.8 billion per year (Fry
32   II,     7.  3.  4|            and leisure accidents and 32 million injured people need
33   II,     8.  2.  1|             be 0.36% in whites and 0.32% in South Asian residents
34   II,     8.  2.  1|       present with a prevalence of 0.32% (Rantakallio and von Wendt,
35   II,     9.  1.  1|            Curr. Res. Anesth. Analg. 32: 260–267.~ ~Atrash HK, Alexander
36   II,     9.  1.  1|             g) or born prematurely (<32 weeks) in 16 European centres:
37   II,     9.  2.  3|              to 29.1% in Ireland and 32.2% in the United Kingdom.
38   II,     9.  3.  1|         increase in male cases and a 32% rise in female cases between
39   II,     9.  3.  2|             g) or born prematurely (<32 weeks) in 16 European centres:
40   II,     9.  3.  3|             as heterosexual men, but 32% of MSM have had 10 or more
41   II,     9.  5.  3|      Accession Countries than EU-15 (32% vs 29%) with the highest
42   II,     9.  5.  3|    prevalence in 2004 was in Poland (32.0) and the Netherlands (
43  III,    10.  2.  1|      treatment went down from 64% to 32%. Over the 1999–2005 period,
44  III,    10.  2.  1|              UK, only about a third (32%) of five-year-olds had
45  III,    10.  2.  1|            Dent Oral Epidemiol 2004; 32: 69-73.~ ~Bourgeois DM,
46  III,    10.  2.  1|            Dent Oral Epidemiol 2004; 32: 74-76.~ ~ ~Petersen PE (
47  III,    10.  2.  1|          2004) were estimated to be €32.8 billion per year (Fry
48  III,    10.  2.  1|         Spain]. Medicina Clinica 125:32-38 (in Spanish).~ ~Armstrong
49  III,    10.  3.  4|             all age groups, in Italy 32–33% and in Portugal more
50  III,    10.  4.  2|           monitoring scheme. Article 32 of Regulation (EC) 396/2005
51  III,    10.  4.  2|            European consumes Article 32 ;~· peer review of active
52  III,    10.  4.  2|              24, 30 January 1998, 31-32. Available at: htt ~ ~European
53  III,    10.  5.  1|         Communities, 1998, L 330(41):32 Available at: http://eurlex.
54   IV,    11.  6.  3|            income on indirect taxes (32%) than higher income households (
55   IV,    12. 10    |          number of municipalities by 32. An additional 90 municipalities